Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AbbVie (ABBV) Rinvoq Gets FDA Nod for Active Psoriatic Arthritis

The FDA approves AbbVie's (ABBV) Rinvoq for the treatment of adults with active psoriatic arthritis. This is the second FDA-approved indication for the drug.

Pfizer (PFE) COVID Pill Maintains Strong Efficacy, Stock Up

Pfizer's (PFE) COVID-19 pill maintains a substantial reduction in hospitalizations and deaths observed during interim analysis last month in the final analysis of the study data.

Company News for Dec 15, 2021

Companies In The News Are: TSLA, TMX, NEOG, MMM, PFE.

Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?

Style Box ETF report for RDIV

The Zacks Analyst Blog Highlights: Pfizer, Arena Pharma, Merck, Jazz Pharm and Sanofi

The Zacks Analyst Blog Highlights: Pfizer, Arena Pharma, Merck, Jazz Pharm and Sanofi

PFE vs. LLY: Which Stock Should Value Investors Buy Now?

PFE vs. LLY: Which Stock Is the Better Value Option?

Are These Medical Stocks Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Company News for Dec 14, 2021

Companies In The News Are: ARNA, PFE, LLY, FHTX, TPX, NAVI.

Kinjel Shah headshot

Does PFE, ARNA Deal Signal Robust Pharma M&A Activity in 2022?

The Pfizer (PFE)-Arena (ARNA) deal raises hopes that M&A activity will pick up significantly in 2022. as big drugmakers are sitting on huge piles of cash.

Pfizer (PFE) to Buy Arena, Boost Immuno-Inflammatory Pipeline

Pfizer (PFE) signs an agreement to acquire Arena Pharmaceuticals for $6.7 billion in cash. Stock rises.

The Zacks Analyst Blog Highlights: Pfizer, BNTX, Moderna, and J&J

The Zacks Analyst Blog Highlights: Pfizer, BNTX, Moderna, and J&J

SpringWorks (SWTX) & AbbVie Unite for Multiple Myeloma Drug

SpringWorks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogacestat with AbbVie's ABBV-383 for relapsed or refractory multiple myeloma.

Pfizer (PFE) Gets Approval for New Eczema Drug in Europe

Pfizer's (PFE) oral JAK inhibitor, Cibinqo, gets approval for treating atopic dermatitis in adults who are candidates for systemic therapy in Europe.

Pfizer, BioNTech Booster Gets FDA Nod for 16- & 17-Year Olds

FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for 16- and 17-year olds.

J&J's (JNJ) COVID-19 Booster Jab Gets WHO Recommendation

An advisory group of the World Health Organization recommends the booster dose of J&J's (JNJ) COVID-19 vaccine for use in adults.

Kinjel Shah headshot

Pharma Stock Roundup: PFE Booster Works on Omicron, AZN COVID Cocktail Gets FDA Nod

Pfizer (PFE) and BioNTech's COVID-19 booster shot proves effective against the Omicron variant. FDA grants EUA to AstraZeneca's (AZN) cocktail antibody for pre-exposure prophylaxis (prevention) of COVID-19.

Sweta Jaiswal, FRM headshot

ETFs to Play the Reopening Trade as Omicron Fear Subsides

The improved market sentiments have been leading to greater attention and confidence in reopening trades.

Pfizer (PFE) COVID-19 Booster Gives Protection Against Omicron

Pfizer (PFE) and BioNTech announce lab test data that demonstrates that the three doses of their COVID-19 vaccine provide significant protection against the Omicron variant.

Stock Market News for Dec 9, 2021

U.S. stocks closed slightly higher on Wednesday, with major indexes hovering around their record highs, as reports suggested that the Omicron variant of the coronavirus looks less dangerous that it was earlier thought.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

Pfizer (PFE) closed at $51.40 in the latest trading session, marking a -0.62% move from the prior day.

Markets Upbeat on Vaccine Efficacy Against Omicron Variant

Markets Upbeat on Vaccine Efficacy Against Omicron Variant

Mark Vickery headshot

Remedies for Omicron Apparent, Markets Up Again

New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.

Is Principal U.S. MegaCap ETF (USMC) a Strong ETF Right Now?

Smart Beta ETF report for USMC

AbbVie's (ABBV) Rinvoq Meets Goals in Crohn's Disease Study

AbbVie's (ABBV) Rinvoq achieves primary and key secondary endpoints in the first phase III induction study in patients with Crohn's Disease.

Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study

Biohaven's (BHVN) pivotal study evaluating intranasal zavegepant for the acute treatment of migraine in adults meets co-primary endpoints. An NDA for zavegepant is expected to be filed in first-quarter 2022.